ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0867

SARS CoV-2 Continuous Quality Improvement Program: Initiation of a Standardized Protocol for AKI Prevention

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Dossaji, Adam, Baystate Medical Center, Springfield, Massachusetts, United States
  • Khan, Asad H., Baystate Medical Center, Springfield, Massachusetts, United States
  • Hodgins, Spencer, Baystate Medical Center, Springfield, Massachusetts, United States
  • Landry, Daniel L., Baystate Medical Center, Springfield, Massachusetts, United States
  • Engelman, Daniel, Baystate Medical Center, Springfield, Massachusetts, United States
  • Slater, Jonathan, Baystate Medical Center, Springfield, Massachusetts, United States
  • Mcgee, Bill, Baystate Medical Center, Springfield, Massachusetts, United States
  • Germain, Michael J., Baystate Medical Center, Springfield, Massachusetts, United States
Background

During the initial phase of the SARS CoV-2 pandemic our institution had high rates of acute kidney injury (AKI) requiring renal replacement therapy (RRT). Nephrocheck (NC), a renal biomarker, indicating renal stress was the basis of a continuous quality improvement (CQI) program to identify patients at risk for AKI & RRT.

Methods

Patients admitted from 4/17-5/15/2020 were all tested for SARS CoV-2. All positive patients ≥ 18 years old & with a creatinine <2.0 mg were tested with NC. Values ≥ 0.7 led to nephrology consults & utilization of a renal-protective strategy including monitoring volume status, scrutinizing nephrotoxic medications & urine studies.
A “Plan-Do-Study-Act” approach was used to increase utilization of NC and the resulting protocol for positive results. Intervention was biphasic with a follow up maintenance phase, each lasting 10 days. Phase 1 was adding NC to the SARS CoV2 admission order set & Phase 2 was educating hospitalist providers about using and interpreting NC to increase appropriate nephrology consults. Education was reinforced with protocol cards & reminders via encrypted text services. Additionally, intervention team members reviewed charts daily & reminded providers in real time.

Results

In Phase 1, 58% of the SARS CoV-2 positive patients had a NC but only 48% of NC positive patients had a renal consult. In Phase 2, 79% of SARS CoV-2 positive patients had a NC with 80% of positive patients getting a renal consult. In the maintenance phase, 67% of SARS CoV-2 positive patients had NC with 59% of NC positive patients getting a renal consult.

Conclusion

During our CQI project, efforts to mitigate severe AKI by using a biomarker-based alert for nephrology consultation saw the number of SARS CoV2 positive patients screened with NC & the number of positive NC patients seen by nephrologists rise significantly. Barriers to implementation included the weekly turn-over of house staff & a reliable alert system to ensure adequate screening. The multidisciplinary team reviewing charts and reminding hospitalists of the protocol also helped significantly but was difficult to sustain.